Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled dose-ranging study of VAY736 in primary Sjögren's syndrome
MOH_2017-11-21_000603Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in primary Sjögren's syndrome (5 arms), sponsored by Novartis. Started Aug 2017; status: completed.
02
Drugs
ianalumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2017-11-21_000603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-21_000603.